Advanced visualization and AI leader TeraRecon, a ConcertAI company, is proud to announce its strategic partnership with GLEAMER, a leading provider of AI solutions for medical imaging. By joining forces, the two companies aim to advance the field of radiology by integrating GLEAMER’s BoneView and ChestView solutions into TeraRecon’s Eureka Clinical AI Platform.
GLEAMER’s BoneView (FDA) and BoneView (CE), which offer AI-powered bone fracture identification, will seamlessly integrate with the Eureka Clinical AI platform. Furthermore, Gleamer’s ChestView (CE), an innovative AI solution for pulmonary nodule detection, will also be incorporated, expanding the platform’s diagnostic capabilities.
“We are thrilled to partner with GLEAMER and integrate their advanced AI algorithms into the Eureka Clinical AI platform,” said Dan McSweeney, President of TeraRecon. “This collaboration perfectly aligns with our commitment to deliver cutting-edge solutions that revolutionize medical imaging and enhance patient outcomes.”
“We are thrilled to join forces with TeraRecon, and to make BoneView and ChestView available to all TeraRecon customers,” said Christian Allouche, CEO and co-founder of GLEAMER. “It is inspiring to be part of this partnership and to offer tools that aim to assist busy radiographers, radiologists, and clinicians to manage patients at the point of care better, adding value for both staff and the patients.”
The addition of GLEAMER’s BoneView will aid radiologists, orthopedic surgeons, emergency physicians, family physicians, and physician assistants alike. BoneView identifies fractures in X-ray images and submits them to radiologists for final validation, providing healthcare professionals with a safe, reliable, time-saving, and user-friendly tool.
ChestView AI is designed to assist radiologists and clinicians in triaging cases and increasing diagnostic performances on chest X-rays. It detects pneumothorax, pleural effusion, alveolar syndrome consolidation, nodules, and mediastinal mass on both standing and bedside acquisitions.
SOURCE: PRNewswire
